Literature DB >> 8285624

Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.

T Q Tan1, E O Mason, C N Ou, S L Kaplan.   

Abstract

Ten neonates with persistent staphylococcal bacteremia (positive blood cultures for > or = 5 days despite appropriate antibiotic therapy) received intravenous (i.v.) rifampin in combination with vancomycin with or without aminoglycoside. Their mean birth weight and length of gestation were 900 g and 27 weeks, respectively. Their ages at the time of infection ranged from 6 to 64 days (mean, 26 days). The staphylococcal isolates were methicillin-resistant Staphylococcus aureus (five isolates), methicillin-susceptible S. aureus (two isolates), and coagulase-negative staphylococci (three isolates). The mean number of bacteremia days prior to administration of i.v. rifampin was 8.3 (range, 5 to 15 days), despite a mean peak vancomycin concentration of 33 micrograms/ml. The dosing of rifampin varied from 2.5 to 10 mg/kg of body weight every 12 h. The mean duration of the rifampin course was 9.7 days (range, 3 to 16 days). Of the 10 neonates, 8 (80%) had sterile blood cultures within 24 h, 1 (10%) had a sterile blood culture within 48 h, and 1 (10%) had a sterile blood culture within 5 days of being placed on i.v. rifampin. No adverse effects were noted in this small group of infants. Seven of the 10 neonates survived; three died from unrelated complications. The MIC ranges of amikacin, vancomycin, and rifampin for the isolates were 2.0 to 16, 0.5 to 2.0, and 0.0013 to 0.04 micrograms/ml, respectively. We also studied eight infants, with a mean age of 23 days, who were receiving i.v. or oral rifampin at a dose of 10 mg/kg/day. For i.v. administration, the peak serum concentration of rifampin (mean +/- standard deviation) was 4.02 +/- 1.22 microgram/ml. The mean trough level at 12 h postifution was 1.11 +/- 0.48 micrograms/ml. For oral administration, the concentrations of rifampin in serum ranged from 0.59 to 2.86 micrograms/ml (mean, 1.86 +/- 0.96 microgram/ml) at 2 h postingestion, increasing to a peak concentration of 2.8 micrograms/ml at 8 h postingestion. The mean 12-h postingestion level was 0.77 +/- 0.03 microgram/ml. From the study of this limited series of neonates, rifampin appears to be a safe and effective addition to therapy when staphylococcal bacteremia is persistent despite vancomycin treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8285624      PMCID: PMC192398          DOI: 10.1128/AAC.37.11.2401

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Leukocyte function and the development of opsonic and complement activity in the neonate.

Authors:  G H McCracken; H F Eichenwald
Journal:  Am J Dis Child       Date:  1971-02

3.  Effect of ampicillin and chloramphenicol against Haemophilus influenzae.

Authors:  W E Feldman
Journal:  Pediatrics       Date:  1978-03       Impact factor: 7.124

4.  Decreased bactericidal activity of leukocytes of stressed newborn infants.

Authors:  W C Wright; B J Ank; J Herbert; E R Stiehm
Journal:  Pediatrics       Date:  1975-10       Impact factor: 7.124

5.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

Review 6.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

7.  Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations.

Authors:  V Gopal; A L Bisno; F J Silverblatt
Journal:  JAMA       Date:  1976-10-04       Impact factor: 56.272

8.  Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices.

Authors:  G L Archer; M J Tenenbaum; H B Haywood
Journal:  JAMA       Date:  1978-08-25       Impact factor: 56.272

9.  In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus.

Authors:  C U Tuazon; M Y Lin; J N Sheagren
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

10.  The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis.

Authors:  R M Massanari; S T Donta
Journal:  Chest       Date:  1978-03       Impact factor: 9.410

View more
  20 in total

1.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  Pharmacokinetics of First-Line Anti-Tubercular Drugs.

Authors:  Aparna Mukherjee; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2019-03-26       Impact factor: 1.967

3.  Antibiotic therapy in neonatal and pediatric septic shock.

Authors:  Rajesh K Aneja; Ruby Varughese-Aneja; Carol G Vetterly; Joseph A Carcillo
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

4.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

5.  Combination of vancomycin and rifampicin for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates.

Authors:  Luciana Rodriguez-Guerineau; María Dolors Salvia-Roigés; Marisol León-Lozano; José Manuel Rodríguez-Miguélez; Josep Figueras-Aloy
Journal:  Eur J Pediatr       Date:  2013-01-18       Impact factor: 3.183

Review 6.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

7.  Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.

Authors:  Kerry J Welsh; April N Abbott; Evan M Lewis; Jeanelle M Gardiner; Mark C Kruzel; Cole T Lewis; John F Mohr; Audrey Wanger; Lisa Y Armitige
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

Review 8.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

9.  Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates.

Authors:  N Margreth van der Lugt; Sylke J Steggerda; Frans J Walther
Journal:  BMC Pediatr       Date:  2010-11-19       Impact factor: 2.125

10.  Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.

Authors:  Wyatt J Roth; Candice B Kissinger; Robyn R McCain; Bruce R Cooper; Jeremy N Marchant-Forde; Rachel C Vreeman; Sophia Hannou; Gregory T Knipp
Journal:  AAPS J       Date:  2013-04-18       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.